InvestorsObserver
×
News Home

Crinetics Pharmaceuticals Inc (CRNX) is up 5.88% in a Week, Should You Buy?

Wednesday, November 29, 2023 12:05 PM | InvestorsObserver Analysts

Mentioned in this article

Crinetics Pharmaceuticals Inc (CRNX) is up 5.88% in a Week, Should You Buy?

Crinetics Pharmaceuticals Inc (CRNX) is near the top in its industry group according to InvestorsObserver. CRNX gets an overall rating of 77. That means it scores higher than 77 percent of stocks. Crinetics Pharmaceuticals Inc gets a 94 rank in the Biotechnology industry. Biotechnology is number 54 out of 148 industries.

Overall Score - 77
CRNX has an Overall Score of 77. Find out what this means to you and get the rest of the rankings on CRNX!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 77 means the stock is more attractive than 77 percent of stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Crinetics Pharmaceuticals Inc Stock Today?

Crinetics Pharmaceuticals Inc (CRNX) stock is trading at $31.70 as of 11:58 AM on Wednesday, Nov 29, an increase of $0.35, or 1.12% from the previous closing price of $31.35. The stock has traded between $31.46 and $32.55 so far today. Volume today is less active than usual. So far 88,031 shares have traded compared to average volume of 791,194 shares. Click Here to get the full Stock Report for Crinetics Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App